Stryker Corporation, a global leader in medical technologies, reported a 6.1% increase in revenue and EBITDA of $3.45 billion for the first half of 2026. Management forecasts organic revenue growth between 8.3% and 9.3% for the full year, with adjusted earnings per share projected at $14.95 to $15.10. The company benefits from strong product innovation and favorable demographic trends, though its valuation remains fair, supporting a Hold rating. Investors should watch for continued steady growth driven by these positive factors.
As of Oct 27, 2026 02:21 WIB, Stryker Corporation (SYK) trades at USD 304.82 on Pluang, down 0.76% for the day. This price sits closer to its 52-week low of USD 269.75 than its 52-week high of USD 387.46, indicating it is currently valued below its peak range. The stock's dividend yield stands at 1.15%, reflecting moderate income potential compared to its market cap of $117.81 billion.
